News & Media

Torqur Receives European Commission Orphan Drug Designation for Bimiralisib in Thymic Epithelial Tumours

Complete Genomics Appoints Lauren Selig to Board of Directors

Complete Genomics Press Release Announces Planned Appointment of Ed McMullen to Board of Directors

Featured in Global Family Office Community Journal 2026: Swiss Rockets Charts the Future of Preventive Healthcare

Rocket Isotopes AG Secures Strategic Leadership in Terbium-161 Production to Power the Next Generation of Radioligand Therapies

Torqur AG to Present Clinical Progress in Actinic Keratosis Program at the 7th Dermatology Drug Development Summit Europe 2026

Swiss Rockets Appoints Dana Novac, MD, MA, as Chief Medical Officer

Swiss Rockets Collaborates with Lonza to Advance Torqur’s Oncology Drug Candidate Bimiralisib into Late-Stage Clinical Development

Swiss Rockets AG Appoints Prof. Dr. Andreas Türler as Chief Radiochemist

Complete Genomics Highlights DNBSEQ-T7+ at AGBT 2026, Expanding High-Throughput Sequencing Capability

A Defining Milestone for Swiss Rockets and Complete Genomics

CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform

Complete Genomics Enters Definitive Agreement to Be Acquired by Swiss Rockets AG

Swiss Rockets Appoints former Roche Senior Executive Tiffany Payette as Chief Corporate Affairs and Investor Relations Officer

Swiss Rockets AG Sponsored and Participated with an Exhibition Booth at the 8th Theranostics World Congress 2026 in Cape Town